Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14968861 | 0.95 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL2589949 | 0.89 | CHEK1 (0.57) | CHEK1 | |
| SCHEMBL14965450 | 0.87 | CHEK1 (0.49) | CHEK1 | |
| SCHEMBL14965448 | 0.84 | CHEK1 (0.53) | CHEK1 | |
| SCHEMBL2595565 | 0.84 | CHEK1 (0.65) | CHEK1 | |
| SCHEMBL14774903 | 0.83 | CHEK1 (0.57) | CHEK1 | |
| SCHEMBL14965101 | 0.83 | CHEK1 (0.56) | CHEK1 | |
| SCHEMBL14761987 | 0.81 | CHEK1 (0.68) | CHEK1 | |
| SCHEMBL16195589 | 0.81 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL14965449 | 0.79 | CHEK1 (0.57) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2780331-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | Sentinel Oncology Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | CHEK1 36/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | CHEK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.